Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Free access | 10.1172/JCI110703

Specific Binding Sites for Triiodothyronine in the Plasma Membrane of Rat Thymocytes: CORRELATION WITH BIOCHEMICAL RESPONSES

Joseph Segal and Sidney H. Ingbar

Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215

Harvard-Thorndike Laboratory of Beth Israel Hospital, Department of Medicine, Beth Israel Hospital, Boston, Massachusetts 02215

Harvard Medical School, Boston, Massachusetts 02215

Find articles by Segal, J. in: PubMed | Google Scholar

Charles A. Dana Research Institute, Beth Israel Hospital, Boston, Massachusetts 02215

Harvard-Thorndike Laboratory of Beth Israel Hospital, Department of Medicine, Beth Israel Hospital, Boston, Massachusetts 02215

Harvard Medical School, Boston, Massachusetts 02215

Find articles by Ingbar, S. in: PubMed | Google Scholar

Published November 1, 1982 - More info

Published in Volume 70, Issue 5 on November 1, 1982
J Clin Invest. 1982;70(5):919–926. https://doi.org/10.1172/JCI110703.
© 1982 The American Society for Clinical Investigation
Published November 1, 1982 - Version history
View PDF
Abstract

As a prerequisite to studies of whether the plasma membrane of the rat thymocyte contains specific, saturable binding sites for the thyroid hormone 3,5,3′-triiodothyronine (T3), a method was developed for the isolation of a plasma membrane fraction from these cells. As judged from both electron microscopic and marker enzyme studies, the fraction was composed principally of plasma membrane vesicles, was free of nuclear contaminants, and was only slightly contaminated with other subcellular components. At 37°C and pH 7.4, binding of [125I]T3 by the fresh membrane preparation was rapid, reaching a maximum at 5 min and then declining with time, so that by 60 min binding was virtually nil. Decreased binding with time was due to a loss of functional binding sites, but did not reflect desensitization, since the decrease in binding activity with time was independent of the presence or absence of T3. Scatchard analysis of saturation studies revealed the presence of two binding sites, one with an apparent dissociation constant (Kd) of 0.95 nM and a maximum capacity of 5.3 × 1010 sites/100 μg protein, and the other with an apparent Kd of 25 nM and a binding capacity of 1.4 × 1012 sites/100 μg protein. Measurement of the ability of several thyronine analogues to inhibit the binding of [125I]T3 revealed the following rank order of potency: l-T3 > l-T4 > d-T3 = d-T4 > l-3,5-T2 > rT3 > d,l-thyronine. Binding of T3 was inhibited by the omission of calcium from the medium or by the addition of the beta adrenergic antagonist alprenolol. As judged from studies of the lower affinity binding site, these manipulations decreased the affinity, but not the number, of binding sites for T3. The relative potencies of thyronine analogues to inhibit the binding of [125I]T3 were generally parallel to their previously reported potencies in stimulating the uptake of the sugar analogue 2-deoxy-glucose (2-DG) in intact rat thymocytes in vitro. Further, the inhibition of T3-binding produced by l-alprenolol or by excluding calcium from the medium resembled the previously reported inhibition that these manipulations produce with respect to T3-induced enhancement of 2-DG uptake. These findings suggest that the binding sites for T3 present in the plasma membrane of rat thymocytes act as functional receptors linked to the stimulation of 2-DG uptake that T3 induces in these cells.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 919
page 919
icon of scanned page 920
page 920
icon of scanned page 921
page 921
icon of scanned page 922
page 922
icon of scanned page 923
page 923
icon of scanned page 924
page 924
icon of scanned page 925
page 925
icon of scanned page 926
page 926
Version history
  • Version 1 (November 1, 1982): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts